# Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer

> **NCT03279250** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 86 (actual)

## Conditions studied

- Prostate Adenocarcinoma
- Stage IIB Prostate Cancer AJCC v8
- Stage IIC Prostate Cancer AJCC v8
- Stage IIIA Prostate Cancer AJCC v8
- Stage IIIC Prostate Cancer AJCC v8

## Interventions

- **DRUG:** Abiraterone Acetate
- **DRUG:** Apalutamide
- **BIOLOGICAL:** Gonadotropin-releasing Hormone Analog
- **DRUG:** Prednisone
- **PROCEDURE:** Radical Prostatectomy

## Key facts

- **NCT ID:** NCT03279250
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-13
- **Primary completion:** 2021-05-11
- **Final completion:** 2021-05-11
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2022-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03279250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03279250, "Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03279250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*